



## **BISON CAPITAL PARTNERS V, LP ANNOUNCES SALE OF APEX INNOVATIVE SCIENCES, INC.**

SANTA MONICA, CA (June 16, 2022) – Bison Capital Partners V, LP (“Bison Capital”) has announced the sale of Apex Innovative Sciences, Inc. (“Apex” or the “Company”) to CenExel Clinical Research, Inc. (“CenExel”). Apex is the industry leading independent operator of clinical trial sites focused on complex clinical trial studies for central nervous system (“CNS”) indications. Apex was formed in 2019 in conjunction with Bison Capital’s investment and the merger of CNS Network and Hassman Research Institute, complemented by the acquisition of Clinical Trial Centers Alliance, a leading coordinator of clinical trial site studies for sponsors and clinical research organizations.

Apex consists of five prominent clinical research sites across California and New Jersey with significant expertise in early phase complex clinical trials and particular emphasis on central nervous system indications. CNS Network will continue to be led by Dr. David Walling (Co-Founder of Apex and its former Chief Clinical Officer) and HRI will continue under the direction of Dr. Howard Hassman (Co-Founder of Apex and its former Chief Executive Officer). Both leaders have decades of experience conducting Phase I-IV studies across a variety of CNS medical specialties. Apex is committed to providing scientific, technological, and organizational expertise in Phase I-IV clinical trials, including Neurology, Psychiatry, Addiction, Asian Bridging, Pain, Healthy Subjects and General Medicine.

“The founders and management team at Apex have been tremendous leaders and partners. It has been a privilege to invest in and partner with this organization. We are excited about this milestone and the opportunity ahead for Apex as the company expands on its expertise and differentiation within complex early phase clinical trials,” said Lou Caballero, Partner at Bison Capital.

“We are very pleased to be joining the CenExel site network,” said Dr. Howard Hassman. “However, we cannot help but look back at the road to get here, particularly the decision to partner with Bison Capital in the funding and formation of Apex in 2019. Bison’s hands-on approach and role in our partnership proved paramount to reaching this successful outcome for Apex.”

“We are thankful to have had the opportunity to partner with Bison Capital and recognize the value of the expertise and experience they brought to bear for the benefit of our organization,” said Dr. David Walling.

### **ABOUT APEX INNOVATIVE SCIENCES, INC.**

Apex Innovative Sciences, Inc. is a global provider of clinical development and site services. Apex represents the consolidation of core businesses including Hassman Research Institute, CNS Network and Clinical Trial Centers Alliance. The expanded team collaborates to provide quality, efficiency, and value in the development of innovative medicines. Apex helps sponsors achieve go/no-go decisions, reduce development costs, and deliver high quality results. Apex is committed to providing scientific, technological, and organizational expertise in Phase I-IV clinical trials, including Neurology, Psychiatry, Addiction, Asian Bridging, Pain, Healthy Subjects and General Medicine. The company prides itself on delivering the highest scientific and clinical quality for its client partners and participants. For more information visit [www.apexsci.com](http://www.apexsci.com)

### **ABOUT BISON CAPITAL**

Bison Capital is a Los Angeles and New York based private equity firm that makes growth capital investments in middle-market companies, public or private, for expansion, acquisitions, and balance sheet recapitalizations. The firm's primary investment focus is partnering with entrepreneurs and management teams seeking capital to grow their businesses. [www.bisoncapital.com](http://www.bisoncapital.com)

To further discuss, please contact:

**Lou Caballero** at 310-260-6573 or by email at [lcaballero@bisoncapital.com](mailto:lcaballero@bisoncapital.com)

**John Voge** at 310-260-6575 or by email at [jvoge@bisoncapital.com](mailto:jvoge@bisoncapital.com)

**Bison Capital Asset Management, LLC**

233 Wilshire Boulevard, Suite 425, Santa Monica, CA 90401 T: 310.260.6570 780 Third  
Avenue, 30th Floor, New York, NY 10017 T: 646.792.2080